Overview

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Status:
RECRUITING

Trial end date:
2031-04-15

Target enrollment:

Participant gender:

Summary

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

Phase:

PHASE3

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborators:

Alliance for Clinical Trials in Oncology
ECOG-ACRIN Cancer Research Group
NRG Oncology
SWOG Cancer Research Network

Treatments:

abiraterone
apalutamide
darolutamide
Docetaxel
enzalutamide